OncoTargets and Therapy

Journal Information
ISSN / EISSN : 11786930 / 11786930
Current Publisher: Dove Medical Press Ltd. (10.2147)
Total articles ≅ 3,659
Current Coverage
Archived in

Latest articles in this journal

OncoTargets and Therapy; doi:10.2147/ott

Abstract:An international, peer-reviewed journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. In terms of therapy, palliative care is also included as part of the overall patient care process.
Shasha Li, Jingjing Li, Zujiang Yu
OncoTargets and Therapy, Volume 12, pp 5537-5544; doi:10.2147/ott.s196925

Abstract:Tumor suppressive functions of LZTFL1 in hepatocellular carcinoma
Kai Xue, Yi-Nan Wang, Xue Zhao, Hong-Xin Zhang, Dan Yu, Chun-Shun Jin
OncoTargets and Therapy, Volume 12, pp 5525-5536; doi:10.2147/ott.s198422

Abstract:Synergistic effect of meta-tetra(hydroxyphenyl)chlorin-based photodynamic therapy followed by cisplatin on malignant Hep-2 cells
Zi-Yi Xu, Jun-Ling Li
OncoTargets and Therapy, Volume 12, pp 5467-5484; doi:10.2147/ott.s194870

Abstract:Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer Zi-Yi Xu, Jun-Ling LiDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the epidermal growth factor receptor (EGFR) has revolutionized the management of non-small-cell lung cancer (NSCLC). Because these drugs are commonly used in combination with other types of medication, the risk of clinically significant drug–drug interactions (DDIs) is an important consideration, especially for patients using multiple drugs for coexisting medical conditions. Clinicians need to be aware of the potential for clinically important DDIs when considering therapeutic options for individual patients. In this article, we describe the main mechanisms underlying DDIs with the EGFR-TKIs that are currently approved for the treatment of NSCLC, and, specifically, the potential for interactions mediated via effects on gastrointestinal pH, cytochrome P450-dependent metabolism, uridine diphosphate-glucuronosyltransferase, and transporter proteins. We review evidence of such DDIs with the currently approved EGFR-TKIs (gefitinib, erlotinib, afatinib, osimertinib, and icotinib) and discuss several information sources that are available online to aid clinical decision-making. We conclude by summarizing the most clinically relevant DDIs with these EFGR-TKIs and provide recommendations for managing, minimizing, or avoiding DDIs with the different agents.Keywords: drug metabolism, pharmacokinetics, CYP450, UDP-glucuronosyltransferase, P-glycoprotein
Cuiping Jin, Xiaojin Gong, Yumin Shang
OncoTargets and Therapy, Volume 12, pp 5425-5436; doi:10.2147/ott.s205522

Abstract:GLUT5 increases fructose utilization in ovarian cancer
Lin Li, Zuohui Zhao, Wenguo Jiang, Jisheng Guo, Shuping Zhang
OncoTargets and Therapy, Volume 12, pp 5395-5404; doi:10.2147/ott.s208637

Abstract:Identification and functional characterization of Lys-trimethylation of lactate dehydrogenase A
Jianwu Jia, Jing Wang, Meifeng Yin, Yongdong Liu
OncoTargets and Therapy, Volume 12, pp 5437-5448; doi:10.2147/ott.s213026

Abstract:MicroRNA-605 directly targets SOX9 to alleviate the aggressive phenotypes of glioblastoma multiforme cell lines by deactivating the PI3K/Akt pathway
Hang Zhao, Guangyong Chen, Huaxin Liang
OncoTargets and Therapy, Volume 12, pp 5415-5424; doi:10.2147/ott.s210128

Abstract:Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis
Weiwei Kong, Jia Wei, Juan Liu, Yudong Qiu, Jiong Shi, Jian He, Mu Su, Mingzhe Xiao, Baorui Liu
OncoTargets and Therapy, Volume 12, pp 5389-5393; doi:10.2147/ott.s208926

Abstract:Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report
Guang Shi, Hong Zhang, Qiong Yu, Chunmei Hu, Youbo Ji
OncoTargets and Therapy, Volume 12, pp 5335-5354; doi:10.2147/ott.s198750

Abstract:GATA1 gene silencing inhibits invasion, proliferation and migration of cholangiocarcinoma stem cells via disrupting the PI3K/AKT pathway